Leqembi seeks full approval, while Takeda hopes for a dengue green light and Verrica looks to break its streak of bad luck.
Key catalysts lie ahead for Amgen, Argenx, Point Biopharma and Novo Nordisk.
J&J moves FcRn towards a big new therapy area, while Bristol, Merck, Astrazeneca and Daiichi Sankyo await important oncology catalysts.
An outcomes trial could increase demand for Wegovy even further – if pricing, and production, can be worked out.
Pdufa dates are also set for Sarepta and UCB, and panels will discuss Leqembi and Beyfortus.
SRP-9001 heads for its month of regulatory probing, as vaccines from GSK and Pfizer, and Genmab and Abbvie’s bispecific, await FDA approval decisions.
Forthcoming data will see the group take on Horizon, but subcutaneous projects could pose the real threat.
Seres and Pfizer are also set for upcoming FDA Pdufa decisions, and a panel is scheduled for Astrazeneca and Merck’s Lynparza.
Important ovarian cancer data are ahead for Immunogen and Mersana, while Disc Medicine eyes a rare metabolic disorder.